Fundraising Fox
3B Future Health Fund
Venture capitalMonaco · Pre-Seed–Late Stage · 11 people tracked
Find your way into 3B Future Health Fund
183 people in our graph share verified history with the 3B Future Health Fund team — schools, employers, funds. One of them is your warm intro.
Investment thesis
3B Future Health Fund backs early-stage and clinical-development-stage healthcare companies with potential first-in-class assets, revolutionary science, experienced management and strong investor syndicates. It concentrates entirely on healthcare, prioritizing oncology and rare diseases with high unmet patient need, and is drug-modality agnostic. Initial investments are typically made at Series A, though sometimes earlier. The 10-year fund plans a diversified portfolio of 10-15 companies, investing up to $12 million per company, seeking board positions and reserving capital for follow-on rounds. Holdings are expected to last five to eight years, or less if value-inflection exits arise. Targets are based in the US, Europe and Israel.
Source: firm website, verified Aug 3, 2026.
Team · 11 people
from the firm's website & public directories
What they invest in
from 20 of 24 portfolio companiesBiotech ×18Healthtech ×13Medical Devices ×8Digital Health ×4AI & Machine Learning ×3Deep Tech ×3Cleantech ×1Crypto & Web3 ×1
HQs:United States×8Italy×2France×1United Kingdom×1Sweden×1
Investments · 24 tracked
founders shown can be your intro pathBy year:2025 · 12024 · 12023 · 12022 · 32021 · 22020 · 12018 · 110 dated
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)inBryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)inDavid Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Co-investorsAlly Bridge GroupDecheng CapitalVivo CapitalAvoro VenturesOrbiMed
Gain Therapeutics is a biotechnology company that develops small molecule drugs targeting allosteric binding sites on disease-related proteins, using its computational Magellan platform to discover compounds that stabilize or destabilize proteins to treat central nervous system disorders, lysosomal storage diseases, metabolic disorders, and oncology; its lead candidate GT-02287 is in Phase 1b testing for Parkinson's disease.
AI & Machine LearningBiotechDeep TechDigital HealthMedical DevicesBethesda, US
Gene Mack(President, Chief Executive Officer and Director)in
BoardMarianne Bjordal(Director)inLorenzo Leoni(Director)inKhalid Islam(Director)Jeffrey Riley(Director)Eric I. Richman(Executive Officer, Director)
Co-investorsTiVenture SAAllele Capital Partners
AnaCardio is a Swedish clinical-stage biopharmaceutical company developing novel drugs to treat heart failure, with its lead program AC01 in phase 1b/2a clinical development.
BiotechHealthtechMedical DevicesStockholm, SE
Lars H. Lund(Founder)
Co-investorsIndustrifondenNovo HoldingsPureos BioventuresSound Bioventures
Greenbone Ortho develops orthopedic medical products and constantly pursues clinical innovation and new applications.
BiotechCleantechHealthtechMedical DevicesNew MaterialsFaenza, IT
Anna Tampieri(Chairman & Director)Saverio Gellini(Chief Executive Officer & Director)inAndrea Cha(Chief Operating Officer)inVanessa Bonomi(Chief Quality Regulatory Officer)inPaolo Sala(Chief Financial Officer)inSusanna Salvagno(Chief Medical & Scientific Officer)in
Co-investorsCDP Venture CapitalItalian Angels for Growth
Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution.
AI & Machine LearningBiotechDeep TechTrento, IT
Emiliano Biasini(Co-founder)inPietro Faccioli(Co-founder)inGiovanni Spagnolli(Co-founder, CTO)inMaria Letizia Barreca(Co-founder)inGraziano Lolli(Co-founder)
Co-investorsCDP Venture CapitalSeroba Life SciencesV-Bio VenturesVertis SGRVI PartnersClaris Ventures+1 more
Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.
BiotechHouston, US
Alice Bexon(Executive Officer)inClifford J. Stocks(Director, Executive Officer)inKamal D. Puri(Executive Officer)inChris Russell(Executive Officer)inRuss Hawkinson(Executive Officer)
BoardSteven Gillis(Director)in
Board seatRoberto De Ponti· per SEC Form D
Co-investorsCanaan PartnersGreatPoint VenturesRiverVest Venture PartnersAlexandriaARCH Venture PartnersBering Capital+5 more
Domain Therapeutics is a clinical-stage biopharmaceutical company developing GPCR-targeting therapies to address unmet medical needs in immuno-oncology and inflammation.
BiotechDigital Health
Co-investorsCTI Life Sciences Fund L.P.adMare BioInnovationsOmnes CapitalPanacea VentureSeventure Partners
Epsilogen develops antibody therapeutics based on the IgE, IgA, and IgG immunoglobulin isotypes for the treatment of cancer, matching each isotype to specific tumor types and combining isotypes into single antibody molecules.
BiotechHealthtech
Tim Wilson(Chief Executive Officer)Kevin FitzGerald(Chief Scientific Officer)inCristina Oliva(Chief Medical Officer)inNick Robbins-Cherry(Chief Financial Officer)inElizabeth Hardaker(Chief Translational Science Officer)
Co-investorsAlbionVCBioGeneration VenturesEpidarex CapitalGlobal BioAccess FundNovartis Venture FundUCL Technology Fund
BiotechPlymouth Meeting, US
Niranjan Y. Sardesai(Executive Officer, Director)inLaurent Humeau(Director)James Eadie(Director)Samuel Broder(Director)Sangwoo Lee(Director)Casey Cunningham(Director)
iOnctura is a clinical-stage drug development company developing precision oral small-molecule therapies targeting the tumor-stroma-immune interface, with a pipeline including roginolisib and cambritaxestat in cancers such as uveal melanoma and pancreatic cancer.
BiotechDeep TechHealthtechMedical Devices
Catherine Pickering(Co-Founder & CEO)inLars van der Veen(Co-Founder & CSO)inMichael Lahn(CMO)inElizabeth Holt(CBO)inSteven Sciuto(CFO)inMichelle Tsai(COO)in
Co-investorsInkefM VenturesVI PartnersXGEN VentureJohnson & Johnson Innovation – JJDC
Kither Biotech is a clinical-stage biotech company developing inhaled cell signal transduction modulators targeting the PI3Kγ signaling axis for respiratory diseases such as COPD, non-cystic fibrosis bronchiectasis, cystic fibrosis, and idiopathic pulmonary fibrosis.
BiotechHealthtech
Co-investorsCDP Venture CapitalClaris VenturesElysia CapitalItalian Angels for Growth
Lite Strategy, Inc.
BiotechCrypto & Web3FintechHealthtechSan Diego, US
David M. Urso(Executive Officer)inDaniel P. Gold(Executive Officer, Director)Brian G. Drazba(Executive Officer)inMr. File(Chief Executive Officer & Board Member (former CFO))Justin (Jay) File(CEO, CFO)inKevan E. Clemens(Director)
Co-investorsAisling CapitalGSRNew Enterprise Associates (NEA)Amzak HealthBiotechnology Value FundVivo Capital
Neophore develops a small-molecule therapeutic that transiently inhibits DNA Mismatch Repair (MMR) to convert MMR-proficient tumours into an MMR-deficient state, making them responsive to cancer immunotherapy.
AI & Machine LearningBiotechLongevity
Co-investorsAstellas Venture Management LLCClaris VenturesNeva Sgr.
On Target Laboratories is a company of scientists and researchers focused on cancer surgery, developing products to support surgical oncology.
BiotechHealthtechMedical Devices
Bill Peters(President, Chief Executive Officer, and Board Member)inRod MacLeod(Chief Financial Officer)inTommy Lee(Senior Vice President of Clinical Operations)inCatherine Brisson(Vice President of Regulatory Affairs and Quality)Anne Fornicola(Vice President of Chemistry, Manufacturing and Controls)inScott Huennekens(Executive Chairperson)in
Co-investorsCerity Partners VenturesElevate VenturesH.I.G. CapitalH.I.G. HealthBridge PartnersH.I.G. BioHealth Partners
A precision oncology company providing genomic testing and resources to support cancer care decisions, operating under Labcorp Oncology.
BiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)inLuis A. Diaz, Jr.(Executive Officer, Director, Promoter)Sam Angiuoli(Executive Officer)inSian Jones(Executive Officer)inLisa Kann(Executive Officer)inAnthony Newton(Executive Officer)
Co-investorsCatalio Capital Management, LPCo-Win VenturesNew Enterprise Associates (NEA)Windham Capital PartnersVensana Capital
QuantuMDx develops point-of-care molecular diagnostics platforms and assays for detecting infectious diseases including sexually transmitted infections, antimicrobial resistance, respiratory viruses, and other pathogens.
Digital HealthHealthtechMedical DevicesNewcastle upon Tyne, GB
Elaine Warburton(Co-Founder and former CEO)
Co-investorsAdjuvoDEFTA Partners
Roca Therapeutics develops first-in-class small molecule therapies for patients with neovascular retinal diseases.
BiotechHealthtechMedical DevicesNice, FR
Obtained U.S.
Co-investorsAMR Action Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
FORE US BioAMAL Therapeutics SAGenEpNavion NeurosciencesNovellus
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 3
2 IPOs · 1 acquisitionsAadi BioscienceNASDAQ: WHWKGain TherapeuticsNASDAQ: GANXUtility Therapeuticsacq. by Alembic Pharmaceuticals
Portfolio news
latest coverage across their companiesFrequently asked questions
- How many investments has 3B Future Health Fund made?
- 3B Future Health Fund has 24 tracked investments, 3 of which have exited, including 1 dated in the last 24 months.
- What stage does 3B Future Health Fund invest at?
- 3B Future Health Fund invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What is 3B Future Health Fund's typical check size?
- 3B Future Health Fund typically writes checks of $12M.
- What sectors does 3B Future Health Fund focus on?
- 3B Future Health Fund focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is 3B Future Health Fund located?
- 3B Future Health Fund is headquartered in Monaco, MC.
- Who does 3B Future Health Fund co-invest with?
- 3B Future Health Fund most often shares deals with Claris Ventures, CDP Venture Capital, Italian Angels for Growth, among 45 tracked co-investors.
- What size deals does 3B Future Health Fund back?
- Across 5 deals with disclosed amounts, 3B Future Health Fund has joined rounds of $14M – $86M (median $41M).
Co-investors · 5
Claris Ventures is an early-stage life sciences venture investor that makes equity investments in biopharma companies with strong scientific evidence, providing capital and hands-on support to advance clinical development programs.
The Novartis Venture Fund invests in innovative life science companies, primarily in biotechnology and biopharmaceuticals, at various stages of development across North America and Europe.
Seventure Partners is a European venture capital firm backing innovative companies across life sciences and digital technologies, with additional focus areas in sport & performance and the blue economy.
Seroba is a Dublin-based life sciences venture capital firm investing in early-stage biotech and medtech companies developing new therapeutics and medical devices.
SR One Capital Management is a life sciences venture capital firm that takes a 'back-and-build' approach, providing entrepreneurs with human, intellectual, and financial resources. It emerged from the legacy SR One team formerly part of GSK.
Firms observed investing alongside 3B Future Health Fund, from public investor directories. Shared companies are the overlap with 3B Future Health Fund's recorded portfolio.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests in technology companies from seed to growth stage. Since inception it has backed over 200 companies and raised more than $1.3 billion.
Investinor AS is a Norwegian investment company that partners with founders, entrepreneurs and other investors to help selected promising companies become world-leading.
Kleiner Perkins is a venture capital firm that backs founders across technology and life sciences, from early stage through growth.
Menlo Ventures is an early-stage venture capital firm backing transformative technology companies, with a strong current emphasis on artificial intelligence across enterprise, healthcare, and consumer markets.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.